Alexion Pharmaceuticals Inc ALXN:NASDAQ

Last Price$109.50NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/11/19

Today's Change-1.70(1.53%)
Bid (Size)$107.58 (1)
Ask (Size)$112.21 (1)
Day Low / High$108.91 - 112.87
Volume1.6 M
 

View Biotechnology IndustryPeer Comparison as of 12/11/2019

 

Alexion Pharmaceuticals Inc ( NASDAQ )

Price: $109.50
Change: -1.70 (1.53%)
Volume: 1.6 M
4:00PM ET 12/11/2019
 
 

Agilent Technologies Inc ( NYSE )

Price: $83.42
Change: +0.49 (0.59%)
Volume: 1.7 M
6:30PM ET 12/11/2019
 
 

Incyte Corp ( NASDAQ )

Price: $94.93
Change: -0.79 (0.83%)
Volume: 946.2 K
4:00PM ET 12/11/2019
 
 

Seattle Genetics Inc ( NASDAQ )

Price: $111.34
Change: -2.64 (2.32%)
Volume: 1.5 M
4:00PM ET 12/11/2019
 
 

Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $78.77
Change: -0.66 (0.83%)
Volume: 1.0 M
4:00PM ET 12/11/2019
 

Read more news Recent News

Elliott Insists on 'Proactive' Sale of Alexion
12:19PM ET 12/09/2019 MT Newswires

Hedge fund manager Elliott Advisors maintained its position that a "proactive" sale would be the best approach to maximize the value of Alexion (ALXN)...

Alexion Pharmaceuticals Rejects Elliott's Suggestion to Seek Sale
10:31AM ET 12/06/2019 MT Newswires

Alexion Pharmaceuticals (ALXN) said Friday that its board decided that pursuing a proactive sale process as suggested by Elliott Advisors (UK) Ltd., would...

Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Alexion Pharmaceuticals
3:10PM ET 12/05/2019 MT Newswires

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as...

Insider Trends: Insider at Alexion Pharmaceuticals Sells Stock for Taxes Interrupting 90-Day Buy Trend
6:54PM ET 12/04/2019 MT Newswires

Daniel Bazarko, SVP, Controller, CAO, executed a sale of 1,185 shares of Alexion Pharmaceuticals (ALXN) on Dec 02, 2019, for approximately $135,149 to...

View all Commentary and Analysis

Omeros: Competition Is In Trouble
4:52PM ET 12/09/2019 Seeking Alpha

Dicerna Pharmaceuticals: A Solid Pick For 2020
2:07PM ET 12/06/2019 Seeking Alpha

IBB Is Positioned For Outperformance
3:43PM ET 12/05/2019 Seeking Alpha

ChemoCentryx Brings Hope To Vasculitis Patients, Steroid Therapy Can Play A Smaller Role
2:34PM ET 11/27/2019 Seeking Alpha

Company Profile

Business DescriptionAlexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA. View company web site for more details
Address121 Seaport Boulevard
Boston, Massachusetts 02210
Phone+1.475.230.2596
Number of Employees2,656
Recent SEC Filing12/04/20194
Chief Executive Officer & DirectorLudwig N. Hantson
Chief Commercial, Global Operations Officer & EVPBrian M. Goff
Chief Financial Officer & Executive Vice PresidentAradhana Sarin
Executive VP, Head-Research & DevelopmentJohn J. Orloff

Company Highlights

Price Open$111.51
Previous Close$109.50
52 Week Range$92.56 - 141.86
Market Capitalization$24.2 B
Shares Outstanding221.3 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/03/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings17.03
Earnings per Share$7.79
Beta vs. S&P 500N/A
Revenue$4.1 B
Net Profit Margin31.29%
Return on Equity14.93%

Analyst Ratings as of 11/11/2019

Buy
16
Overweight
3
Hold
4
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset